Juniper Publishers- Drug Design Open Access Journals

  JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF DRUG DESIGNING & DEVELOPMENT Abstract Gemcitabine (2',2'-difluorodeoxycytidine, Gemzar®) is a deoxycytidine analog with pronounced antitumor activity against a variety of solid tumors. As gemcitabine is widely used for the treatment of human cancer, the appearance of resistance is a major obstacle to its clinical efficacy. Therefore, it is very important to understand the mechanisms by which cancer cells evolve chemo-resistance to this drug. Through comprehensive analysis of gene -expression profiles by oligonucleotide microarray analysis and follow -up studies, we have identified a cluster of DNA repair genes whose expression is induced in MDA- MB231 cells in the presence of gemcitabine. Based upon information obtained from this analysis, a testable hypothesis was generated regarding the potential roles of identified DNA repair gene products in mediating chemo resistance to gemcitabine in human cancer. Furthermore...

  JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF DRUG DESIGNING & DEVELOPMENT Introduction Proton pump inhibitors are one of the most frequently prescribed classes of drug in the world because they combine a high level of efficacy with low toxicity. In 2006, expenditure on these drugs was £7bn globally [ 1 ] Yet studies consistently show that proton pump inhibitors are being overprescribed worldwide in both primary and secondary care [ 2 ]. Between 25% and 70% of patients taking these drugs have no appropriate indication. This means that, at the very least, £100m from the National Health Service (NHS) budget and almost £2bn worldwide is being spent unnecessarily on proton pump inhibitors each year. The first generic proton pump inhibitor (omeprazole) was introduced in 2002 and now comprises more than four fifths of all prescriptions for proton pump inhibitors in India. In the five years since the introduction of omeprazole, prescriptions for proton pump ...